Technical Analysis for PTCT - PTC Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 1.40% | |
| Down 3 Days in a Row | Weakness | 1.40% | |
| Oversold Stochastic | Weakness | 1.40% | |
| MACD Bearish Centerline Cross | Bearish | 1.01% | |
| Inside Day | Range Contraction | 1.01% | |
| Lower Bollinger Band Touch | Weakness | 1.01% | |
| Fell Below 20 DMA | Bearish | 0.82% | |
| Fell Below 50 DMA | Bearish | 0.82% | |
| MACD Bearish Signal Line Cross | Bearish | 0.82% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.82% |
| Alert | Time |
|---|---|
| Possible NR7 | about 3 hours ago |
| Up 2% | about 7 hours ago |
| Fell Below Previous Day's Low | about 7 hours ago |
| Up 1% | about 7 hours ago |
| Possible NR7 | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 10/24/2024
PTC Therapeutics, Inc. Description
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Gene Expression Dystrophy Muscular Dystrophy Cystic Fibrosis Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.86 |
| 52 Week Low | 17.53 |
| Average Volume | 605,391 |
| 200-Day Moving Average | 30.29 |
| 50-Day Moving Average | 32.87 |
| 20-Day Moving Average | 33.48 |
| 10-Day Moving Average | 33.79 |
| Average True Range | 1.56 |
| RSI (14) | 38.65 |
| ADX | 15.67 |
| +DI | 15.78 |
| -DI | 27.67 |
| Chandelier Exit (Long, 3 ATRs) | 31.63 |
| Chandelier Exit (Short, 3 ATRs) | 33.70 |
| Upper Bollinger Bands | 36.32 |
| Lower Bollinger Band | 30.64 |
| Percent B (%b) | 0.14 |
| BandWidth | 16.97 |
| MACD Line | -0.17 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.3569 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 33.00 | ||||
| Resistance 3 (R3) | 33.11 | 32.71 | 32.73 | ||
| Resistance 2 (R2) | 32.71 | 32.31 | 32.65 | 32.64 | |
| Resistance 1 (R1) | 32.06 | 32.06 | 31.86 | 31.95 | 32.56 |
| Pivot Point | 31.66 | 31.66 | 31.56 | 31.60 | 31.66 |
| Support 1 (S1) | 31.01 | 31.26 | 30.81 | 30.90 | 30.28 |
| Support 2 (S2) | 30.61 | 31.01 | 30.55 | 30.20 | |
| Support 3 (S3) | 29.96 | 30.61 | 30.11 | ||
| Support 4 (S4) | 29.85 |
